Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The Inje cocktail is a validated combination of five probe drugs designed for high-throughput in vivo phenotyping of major human cytochrome P450 (CYP) enzyme activities. It is used primarily in clinical pharmacology research to simultaneously assess the metabolic activity of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A enzymes. The five components are caffeine (CYP1A2), losartan (CYP2C9), omeprazole (CYP2C19), dextromethorphan (CYP2D6), and midazolam (CYP3A). Each drug serves as a specific substrate for its respective enzyme isoform. The mechanism involves administering all five drugs together and measuring their plasma or urine metabolite ratios to determine individual enzyme activity[1][3][8]. This approach enables efficient evaluation of potential drug-drug interactions or genetic differences in metabolism.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Inje cocktail.